Our 2023 event has concluded
For those who attended, thank you for an incredible event. We are looking forward to returning in March 2024.
ACI created The National Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities and Gene Therapies to provide you with solutions to some of the greatest challenges impeding market access for these products.
We were pleased to have representatives from the USPTO and FDA, as well as, distinguished in-house and outside counsel, that discussed IP and regulatory initiatives that are essential to the proliferation of mRNA, CRISPR, CAR T and more.
2023 sessions included:
- What Every Life Sciences Business Executive and Counsel Need to Know about the mRNA and CRISPR Patent War
- Assessing Competitors, Mapping Opportunities, and Mastering the IP Due Diligence Process
- Best practices for Securing Financing and Capital Formation
- Leveraging the Power of AI, ML, Automation and Data for the Development of Better Medicines
Chief Legal Officer
Beam Therapeutics, Inc.
“We are excited to share the latest trends, challenges and strategic considerations for Novel Therapeutic Modalities and Gene Therapies, as well as take advantage of this unique opportunity to network with the larger community working on these ground-breaking treatments.”
Director & Senior Counsel
Global IP Lead – Gene Therapies
Novartis Gene Therapies
“I am looking forward to this meeting. The science behind novel gene therapies is evolving at a rapid pace and this conference brings together leaders in business, law, and policy from the government, academia, and industry to talk about ways that the legal and regulatory regimes can adapt to keep pace with the science.”
2023 In-House Perspectives from
SVP, Deputy General Counsel
Alexion, AstraZeneca Rare Disease
Senior Patent Counsel Celle & Gene Patent Lead
VP, Head of IP and Legal
Arbor Biotechnologies, Inc.
2023 GOVERNMENT SPEAKERS INCLUDE
Chief of Staff
U.S. Food and Drug Administration (FDA)
Supervisory Patent Examiner, Quality Assurance Specialist
Supervisory Patent Examiner, Bioinformatics
Supervisory Patent Examiner, Immunotherapy and Recombinant Antibodies
Obtain Industry Acumen from
- Alexion, AstraZeneca Rare Disease
- Arbor Biotechnologies, Inc.
- Beam Therapeutics, Inc.
- BioNTech SE
- Ferring Pharmaceuticals
- Novartis Gene Therapies
- Nutcracker Therapeutics
Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as non-transitional for the purposes of CLE accreditation.